The New President of WPC: Malú Gámez Tansey - This is the Beginning of the End

One of the most dramatic consequences of the new framework is the growing focus on the gut.

For years, Parkinson’s was treated almost exclusively as a brain disorder. Increasingly, researchers suspect important parts of the disease process may begin outside the brain entirely.

“It can come from potential exposures to pesticides in your gut,” Tansey said. “It can come from chronic infections.”

Inflammation in the gastrointestinal tract appears capable of increasing alpha-synuclein production in gut tissue. Some researchers believe pathological proteins may then propagate upward along connected neural pathways toward the brain.

Tansey described one hypothesis in which epithelial cells lining the gut initially produce elevated synuclein as part of immune defense. Problems arise when those proteins are transferred into connected neural circuits that cannot safely process them.

“That’s where the problem starts becoming toxic,” she said.

The gut microbiome - the enormous ecosystem of bacteria, viruses and fungi living inside the digestive tract - has consequently become one of the fastest-growing areas in Parkinson’s research. 

Researchers are now studying whether microbial imbalances, intestinal permeability and chronic gastrointestinal inflammation may contribute to neurodegenerative disease progression years before classical symptoms appear.

That possibility could help explain why many Parkinson’s patients experience constipation, sleep disorders or loss of smell long before tremors emerge.

“As soon as we expand our definition of what it’s like to have Parkinson’s disease,” Tansey said, “the numbers are going to balloon.”

The implications are enormous. If Parkinson’s begins years - or even decades - before classical motor symptoms appear, researchers may eventually be able to intervene earlier, before large numbers of neurons are lost.

Why many trials fail

The growing complexity also helps explain one of the field’s deepest frustrations: the repeated failure of clinical trials. Under the traditional framework, Parkinson’s patients were grouped together under a single diagnosis. Biologically, however, they may represent profoundly different conditions.

Some patients may be driven primarily by inflammatory dysfunction. Others by mitochondrial impairment, lysosomal failure, environmental toxicity or specific genetic mutations such as LRRK2.

“The signal-to-noise is terrible,” Tansey said.

A drug that genuinely helps one biological subgroup may appear ineffective once tested across a heterogeneous patient population.

That realization is increasingly pushing Parkinson’s research toward precision medicine - the idea that therapies should be matched to underlying biology rather than outward symptoms alone.

Tansey described experimental approaches in which researchers isolate immune cells from patients’ blood, expose them to different biological stressors in laboratory dishes and observe how those cells respond to potential treatments.

“You will know exactly who your responders are going to be,” she said.

The strategy resembles approaches already used in oncology and autoimmune medicine.

The same thinking increasingly influences how researchers interpret failed neurodegeneration trials more broadly.

Tansey described one recent anti-inflammatory Alzheimer’s trial involving a modified TNF inhibitor designed to suppress harmful inflammation without broadly suppressing the immune system itself. Researchers attempted to enroll patients showing signs of inflammation, but biomarker limitations complicated patient selection.

The trial ultimately failed its primary cognitive endpoint. But when researchers later examined subsets of patients who were both amyloid-positive and strongly inflammatory, they found slower cognitive decline.

For Tansey, the lesson was not that the biology failed. The categorization failed.

Environment and evolution

The broader model also changes how researchers think about causation itself.

For decades, debates in Parkinson’s research often centered on genetics versus environment. Increasingly, researchers suspect the disease emerges through interactions between both.

Tansey described Parkinson’s as a “perfect storm” - not a single insult, but the convergence of many smaller stressors that collectively push vulnerable systems beyond resilience.

Environmental exposure remains particularly difficult to disentangle.

“We have done a lot of bad things to our environment,” she said. “To our foods and water supply.”

But genetics may also carry hidden evolutionary tradeoffs. Mutations in the LRRK2 gene may enhance immune activity earlier in life, potentially offering advantages against infection. Later in life, however, that same heightened inflammatory response may become harmful.

 “What used to be good in a young organism becomes a liability in an older organism,” Tansey said.

Nature, she added bluntly, “doesn’t care about us getting old.”

The idea reframes Parkinson’s not simply as a malfunction, but partly as a consequence of biological systems optimized for survival earlier in life rather than longevity.

Exercise as intervention

The newer framework is also changing how researchers think about exercise.

For years, exercise was often framed as supportive care - useful, but secondary to pharmaceutical intervention. Increasingly, researchers view it as directly relevant to the underlying biology of disease.

“It lowers the inflammation,” Tansey said. “It promotes neurotrophic factors. It’s good for your gut. It’s good for sleep.”

Exercise influences multiple biological systems simultaneously: inflammatory signaling, gut function, sleep quality and production of growth factors that help neurons survive.

“It really is the wonder activity,” she said.

She admitted she initially found the evidence surprising.

“I could never have predicted that was going to work,” she said. “Honestly, I thought - that’s so simple.”

The realization has shifted exercise from lifestyle advice toward something closer to systems-level intervention.

The same systems thinking increasingly extends to sleep. Researchers have become intensely interested in REM sleep behavior disorder, one of the strongest known predictors of Parkinson’s disease years before diagnosis.

“The gut-brain connection goes both ways,” Tansey said.

Artificial Intelligence

As Parkinson’s biology becomes more complex, researchers are increasingly turning toward computational tools capable of analyzing enormous datasets.

Artificial intelligence and machine learning systems are now being used to identify subtle biological patterns across genetics, immune profiling, biomarkers and clinical outcomes.

Tansey believes such systems may become especially valuable in connecting fragmented observations across different scientific disciplines.

“AI is going to really help us pick out the common threads that are central,” she said.

Not because the systems themselves are creative, she argued, but because they can dramatically accelerate pattern recognition across vast scientific literature and experimental data.

Researchers increasingly hope such systems may help identify biological subtypes of Parkinson’s disease long before irreversible degeneration occurs.

Beginning of the End

None of this means Parkinson’s is close to being solved. The disease remains extraordinarily complicated. Clinical failures continue. Fundamental scientific disagreements remain unresolved. Even the role of alpha-synuclein - still central to much of the field - remains heavily debated.

But compared with even a decade ago, the intellectual landscape has shifted dramatically.

Parkinson’s is no longer understood solely as a disorder of dopamine neurons. Increasingly, it is becoming a disease of interconnected systems: immune systems, metabolic systems, gastrointestinal systems and aging systems interacting over time.

That broader framework has also produced something long scarce in neurodegeneration research: cautious optimism. Asked whether neuroscience is still in the early stages of understanding Parkinson’s or approaching a genuine turning point, Tansey did not hesitate.

“I think we are way approaching a breakthrough,” she said.

Then she paused.

“This is the beginning of the end.”

_

Edited on July 2nd to reflect that Tansey is the new president of the WPC.